SUZHOU, China, AccurEdit Therapeutics today announced that its three abstracts have been selected for presentation, including one oral presentation on ART001, at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28^th Annual Meeting being held from May 13-17, 2025, in New Orleans, LA.

ART001 is the only LNP-based in vivo gene editing product that has cleared INDs in both the US and China. It is currently in phase I/IIa studies in China and phase I study in the US.

The two poster presentations focus on ART002 and ARTbase-A1^TM, respectively. ART002 is AccurEdit Therapeutics’ second pipeline product that has achieved nearly 90% reduction in PCSK9 and 56% reduction in LDL-C on average in HeFH patients with critically high LDL-C baselines (>6 mM). ARTbase-A1^TM is AccurEdit Therapeutics’ solely-owned base editor platform that has recently been granted patents in China and the US. 

“We thank the organizing committee of ASGCT for the opportunity to present the latest data on our pipeline products with best-in-class potentials and novel gene-editing tools with industry-leading performances.” said Yongzhong Wang, Ph.D., CEO of AccurEdit Therapeutics. “We look forward to meeting our peers and potential collaborators to discuss the exciting perspective of delivering more efficient, safe and affordable in vivo gene therapeutics for our patients globally.”

Oral Presentation Details

Abstract Title: ART001: Development and Interim Clinical Outcomes of a CRISPR-Based In Vivo Gene-Editing Therapy for Hereditary ATTR
Oral Presentation Date/Time: Friday, May 16, 2025 at 5:15 PM - 5:30 PM CT
Room: Room 393-396

Final Abstract Number: AMA434

Poster Presentation Details

Abstract Title: Efficacy and Safety of ART002, a Single-dose Gene Editing Therapy, in Patients with Severe Heterozygous Familial Hypercholesterolemia
Poster Session Date/Time: Tuesday, May 13, 2025 at 6:00 PM - 7:30 PM CT

Room: Poster Hall Hall I2

Final Abstract Number: AMA562

Abstract Title: Engineering TadA-Derived Base Editors with Enhanced Potency and Safety for non-viral In Vivo Gene Editing
Poster Session Date/Time: Thursday, May 15, 2025 at 5:30 PM - 7:00 PM CT

Room: Poster Hall Hall I2

Final Abstract Number: AMA559